Logo image of PYXS

PYXIS ONCOLOGY INC (PYXS) Stock Fundamental Analysis

NASDAQ:PYXS - Nasdaq - US7473241013 - Common Stock - Currency: USD

1.09  +0.01 (+0.93%)

Fundamental Rating

2

Taking everything into account, PYXS scores 2 out of 10 in our fundamental rating. PYXS was compared to 568 industry peers in the Biotechnology industry. PYXS scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages. PYXS has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

PYXS had negative earnings in the past year.
In the past year PYXS has reported a negative cash flow from operations.
In the past 5 years PYXS always reported negative net income.
In the past 5 years PYXS always reported negative operating cash flow.
PYXS Yearly Net Income VS EBIT VS OCF VS FCFPYXS Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 2024 -20M -40M -60M -80M -100M

1.2 Ratios

With a Return On Assets value of -49.20%, PYXS perfoms like the industry average, outperforming 47.89% of the companies in the same industry.
Looking at the Return On Equity, with a value of -64.04%, PYXS is in line with its industry, outperforming 58.80% of the companies in the same industry.
Industry RankSector Rank
ROA -49.2%
ROE -64.04%
ROIC N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
PYXS Yearly ROA, ROE, ROICPYXS Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 2024 -50 -100 -150 -200

1.3 Margins

With an excellent Gross Margin value of 97.06%, PYXS belongs to the best of the industry, outperforming 95.95% of the companies in the same industry.
PYXS does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 97.06%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PYXS Yearly Profit, Operating, Gross MarginsPYXS Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023 2024 0 -100 -200 -300 -400

More info and screens

4

2. Health

2.1 Basic Checks

PYXS does not have a ROIC to compare to the WACC, probably because it is not profitable.
PYXS has more shares outstanding than it did 1 year ago.
PYXS has more shares outstanding than it did 5 years ago.
PYXS has a worse debt/assets ratio than last year.
PYXS Yearly Shares OutstandingPYXS Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M 50M
PYXS Yearly Total Debt VS Total AssetsPYXS Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

2.2 Solvency

PYXS has an Altman-Z score of -2.60. This is a bad value and indicates that PYXS is not financially healthy and even has some risk of bankruptcy.
The Altman-Z score of PYXS (-2.60) is comparable to the rest of the industry.
A Debt/Equity ratio of 0.00 indicates that PYXS is not too dependend on debt financing.
PYXS has a Debt to Equity ratio (0.00) which is comparable to the rest of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.6
ROIC/WACCN/A
WACC10.31%
PYXS Yearly LT Debt VS Equity VS FCFPYXS Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 2024 0 100M 200M

2.3 Liquidity

PYXS has a Current Ratio of 7.49. This indicates that PYXS is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PYXS (7.49) is better than 71.48% of its industry peers.
A Quick Ratio of 7.49 indicates that PYXS has no problem at all paying its short term obligations.
PYXS has a better Quick ratio (7.49) than 71.65% of its industry peers.
Industry RankSector Rank
Current Ratio 7.49
Quick Ratio 7.49
PYXS Yearly Current Assets VS Current LiabilitesPYXS Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 2024 50M 100M 150M 200M 250M

More info and screens

3

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 48.65% over the past year.
EPS 1Y (TTM)48.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

The Earnings Per Share is expected to decrease by -3.52% on average over the next years.
PYXS is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 44.71% yearly.
EPS Next Y-20.25%
EPS Next 2Y-2.58%
EPS Next 3Y-6.02%
EPS Next 5Y-3.52%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-23.57%
Revenue Next 5Y44.71%

3.3 Evolution

PYXS Yearly Revenue VS EstimatesPYXS Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M 500M
PYXS Yearly EPS VS EstimatesPYXS Yearly EPS VS EstimatesYearly EPS VS Estimates 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 1 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for PYXS. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PYXS. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PYXS Price Earnings VS Forward Price EarningsPYXS Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PYXS Per share dataPYXS EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1

4.3 Compensation for Growth

A cheap valuation may be justified as PYXS's earnings are expected to decrease with -6.02% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.58%
EPS Next 3Y-6.02%

More info and screens

0

5. Dividend

5.1 Amount

PYXS does not give a dividend.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PYXIS ONCOLOGY INC

NASDAQ:PYXS (4/24/2025, 11:21:50 AM)

1.09

+0.01 (+0.93%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)03-18 2025-03-18/bmo
Earnings (Next)05-09 2025-05-09/bmo
Inst Owners41.24%
Inst Owner Change0%
Ins Owners7.68%
Ins Owner Change0%
Market Cap67.13M
Analysts85.71
Price Target8.01 (634.86%)
Short Float %15.69%
Short Ratio10.88
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)8.11%
Min EPS beat(2)-9.51%
Max EPS beat(2)25.73%
EPS beat(4)3
Avg EPS beat(4)26.06%
Min EPS beat(4)-9.51%
Max EPS beat(4)75.69%
EPS beat(8)6
Avg EPS beat(8)25.71%
EPS beat(12)6
Avg EPS beat(12)11.58%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-11.29%
PT rev (3m)-20.29%
EPS NQ rev (1m)11.94%
EPS NQ rev (3m)10.61%
EPS NY rev (1m)14.41%
EPS NY rev (3m)7.66%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 4.16
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.57
EV/EBITDA N/A
EPS(TTM)-0.95
EYN/A
EPS(NY)-1.14
Fwd EYN/A
FCF(TTM)-0.94
FCFYN/A
OCF(TTM)-0.94
OCFYN/A
SpS0.26
BVpS1.96
TBVpS1.92
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -49.2%
ROE -64.04%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 97.06%
FCFM N/A
ROA(3y)-49.59%
ROA(5y)-60.34%
ROE(3y)-65.94%
ROE(5y)-86.11%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.1
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 7.95%
Cap/Sales 1.47%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 7.49
Quick Ratio 7.49
Altman-Z -2.6
F-Score4
WACC10.31%
ROIC/WACCN/A
Cap/Depr(3y)419.47%
Cap/Depr(5y)331.27%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)48.65%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%24.24%
EPS Next Y-20.25%
EPS Next 2Y-2.58%
EPS Next 3Y-6.02%
EPS Next 5Y-3.52%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-23.57%
Revenue Next 5Y44.71%
EBIT growth 1Y16.66%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year-192.76%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y25.22%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y18.44%
OCF growth 3YN/A
OCF growth 5YN/A